When it comes to the significant process that is compiling components for the correct kinase assay for your work, it can be extremely time-consuming and expensive. Having a simple mix-and-read method can take a lot of the stress out of this process. The good news is that you can find a kinase assay kit which
BellBrook Labs was awarded a Phase I Small Business Innovative Research (SBIR) grant of $353,000 from the National Institute on Alcohol Abuse and Alcoholism for pharmacological validation of GIV, a nonreceptor guanine nucleotide exchange factor (GEF), as a therapeutic target for liver fibrosis.  BellBrook will use proprietary high throughput GTPase assay methods to identify small
In Part I of II in this blog series, discussion included the challenges of screening methyltransferases, steps in developing an SAH assay, the experimental assay procedure, assay sensitivity, and reagent stability. Please view the previous post here: Creating a Methyltransferase HTS Assay Using an SAH Riboswitch Part I. Compatibility with Diverse MT Accepter Substrates As

ICBS Conference 2016

  Location: Madison, WI Date: October 24-26   BellBrook Labs’ team of scientists will be presenting the following posters at the International Chemical Biology Society. A Homogenous, Universal Methyltransferase Assay Based on a Microbial Riboswitch Leveraging Aptamers for Detection of Growth Factors in an HTS Compatible Format: An AptaFluor™ VEGF Assay Measuring Drug Residence Times
Did you miss the DOT 2016 meeting in Boston or would like a recap? View the posters and presentations from BellBrook’s scientists below. Posters: Aptamer Based Homogenous Single-Reagent HTS Assay Platform for Human Growth Factors Aniket, Elizabeth Vu, Meera Kumar, Tom Zielinski, Justin Brink, and Robert G. Lowery Determination of Drug Residence Time in a
Riboswitches were discovered in 2002 by Ron Breaker at Yale as RNA-based intracellular sensors of vitamin derivatives. During the last decade, riboswitches have been identified that bind a range of small biomolecules including nucleotides, amino acids, and ions. Riboswitches exert regulatory control of transcription, translation, splicing, and RNA stability. BellBrook scientists used a riboswitch that
BellBrook Labs has been awarded an $860,000 Phase II SBIR grant from the National Institutes of General Medical Sciences to develop an innovative methyltransferase assay for epigenetic drug discovery.  The company’s scientists engineered a fluorescent light switch into a bacterial metabolite sensor to leap-frog the limitations of conventional reagents. Madison, WI – August 31, 2016
Discovery on Target 2016 September 19-22 Westin Boston Waterfront Boston, MA Exhibition Visit Booth #24 to: Discuss BellBrook’s current HTS assays. Share your thoughts on the future of drug discovery. Learn about upcoming AptaFluor™ HTS assays! Presentations/Talks AptaFluor™ Methyltransferase Assay: A Homogenous, Universal HMT Assay Based on a Microbial Riboswitch Tuesday, September 20th – 3:15PM Poster
There are many phosphodiesterase assay kits currently on the market. Comparing the various assays allows pharmaceutical companies to determine for themselves the advantages of using a Transcreener biochemical assay. At BellBrook Labs, located in Madison, WI, we focus on developing HTS assays which can be used to streamline and enhance the drug discovery process. For

Fighting Infection’s Ghost

Aicardi–Goutières syndrome (AGS) is a rare and brutal genetic condition. Most infants born with the syndrome are asymptomatic at birth, but about 1 in 5 have enlarged spleen and liver, elevated liver enzymes in the blood, decreased platelet level, and abnormal neurological responses. Over the first year of life, things get much worse: episodes of